Expect Trikafta to Be a Game Changer for Cystic Fibrosis

February 2020

Trikafta (try-KAF-tuh, elexacaftor/tezacaftor/ivacaftor) will be a game changer for treating cystic fibrosis (CF).

It targets a gene mutation found in nearly 90% of CF patients.

CF transmembrane conductance regulator (CFTR) modulators already on the market...Kalydeco, Orkambi, and Symdeko...target genetic mutations found in fewer than 50% of patients.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote